HighVista Strategies’s Soleno Therapeutics SLNO Stock Holding History

HighVista Strategies’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-165,227	Closed	-$5.53M	–	175
2026 Q1	$5.53M	Buy	165,227 +30,158	+22%	+$1.18M	1.53%	12
2025 Q4	$6.25M	Buy	135,069 +116,369	+622%	+$6.38M	1.61%	15
2025 Q3	$1.26M	Buy	18,700 +5,759	+45%	+$427K	0.31%	103
2025 Q2	$1.08M	Sell	12,941 -1,403	-10%	-$105K	0.4%	106
2025 Q1	$1.02M	Hold	14,344	–	–	0.39%	109
2024 Q4	$645K	Buy	14,344 +3,259	+29%	+$169K	0.24%	120
2024 Q3	$560K	Buy	+11,085	New	+$531K	0.19%	122
2024 Q2	–	Sell	-10,428	Closed	-$446K	–	155
2024 Q1	$446K	Buy	+10,428	New	+$472K	0.16%	123

HighVista Strategies's SLNO Position: Q2 2026 in Review

HighVista Strategies sold out of Soleno Therapeutics (SLNO) in Q2 2026, closing a stake of 165,227 shares — an estimated $5.53M sold.

HighVista Strategies first reported a position in SLNO in Q1 2024 and held it in 8 quarters. The position peaked at $6.25M in Q4 2025. 0 funds tracked by Wall St. Rank hold SLNO as of Q2 2026.

HighVista Strategies reported no remaining Soleno Therapeutics position as of Q2 2026 after selling out during the quarter.
HighVista Strategies sold 165,227 Soleno Therapeutics shares in Q2 2026, an estimated $5.53M.
HighVista Strategies first reported a position in Soleno Therapeutics in Q1 2024 and held it in 8 quarters.
HighVista Strategies's Soleno Therapeutics position peaked at $6.25M in Q4 2025.
0 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2026.

Based on HighVista Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.